文献速递免疫规划传染病防控与疫情报告

20价肺炎球菌结合疫苗在健康成人中的I期试验

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
PubMed 文献 · Vaccine · 2019-09-05

本研究为随机、对照、观察者盲法的I期首次人体试验,纳入66名18-49岁无肺炎疫苗接种史的健康成人,随机接种单剂PCV20或Tdap对照疫苗。结果显示PCV20对全部20种疫苗血清型均诱导显著的IgG和OPA免疫应答,安全性特征与Tdap相似,未发现安全性问题,支持进一步评估。

要点

  • PCV20在健康成人中诱导针对全部20种血清型的显著IgG和OPA应答。
  • PCV20总体安全性特征与Tdap相似,未发现安全性问题。
  • I期数据支持对PCV20开展进一步临床评估。

核心结论

  • PCV20接种耐受性良好,对全部疫苗血清型诱导显著的 function (OPA) 和IgG应答。

研究设计与样本

  • I期首次人体、随机、对照、观察者盲法、两臂平行设计研究。
  • 共纳入66名18-49岁无肺炎疫苗接种史的健康成人,随机接受单剂PCV20或Tdap对照疫苗。

主要发现

  • PCV20诱导针对20种疫苗血清型的IgG几何平均浓度(GMC)和OPA几何平均滴度(GMT)升高。
  • PCV20总体安全性特征与Tdap相似,且与PCV13接种后观察到的安全性特征基本一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Streptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial morbidity and mortality, particularly in those under 2 years of age and those over 65 years of age. While significant progress against S. pneumoniae-related disease has been made as a result of the introduction of pneumococcal conjugate vaccines (PCV7, PCV10 and PCV13), there remains value in further expanding pneumococcal vaccine serotype coverage. Here we present the first report of a 20-valent pneumococcal conjugate vaccine (PCV20) containing capsular polysaccharide conjugates present in PCV13 as well as 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) which are important contributors to pneumococcal disease. METHODS: This Phase I first-in-human study was a randomized, controlled, observer-blinded study with a two-arm parallel design to assess the safety, tolerability, and immunogenicity of PCV20 in adults. A total of 66 healthy adults 18-49 years of age with no history of pneumococcal vaccination were enrolled and randomized to receive a single dose of PCV20 or a licensed tetanus, diphtheria, acellular pertussis combination vaccine (Tdap) control. Local injection site reactions, select systemic symptoms, laboratory studies, and adverse events were assessed. Opsonophagocytic activity (OPA) titers and IgG concentrations were measured in sera collected prior to, and approximately one month (28-35 days) after vaccination. RESULTS: Vaccination with PCV20 elicited substantial IgG and functional bactericidal immune responses as demonstrated by increases in IgG geometric mean concentrations (GMCs) and OPA geometric mean titers (GMTs) to the 20 vaccine serotypes. The overall safety profile of PCV20 was similar to Tdap, and generally consistent with that observed after PCV13 administration. CONCLUSIONS: Vaccination with PCV20 was well tolerated and induced substantial functional (OPA) and IgG responses to all vaccine serotypes. There were no safety issues identified in this Phase 1 study, and the data supported further evaluation of PCV20.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019. PMID: 31495592. doi:10.1016/j.vaccine.2019.08.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。